ABSTRACT
LKB1 is a serine/threonine kinase which is inactivated by mutation in the Peutz-Jeghers polyposis and cancer predisposition syndrome (PJS). We have identified a novel leucine-rich repeat containing protein, LIP1, that interacts with LKB1. The LIP1 gene consists of 25 exons, maps to human chromosome 2q36 and encodes a protein of 121 kDa. LIP1 appears to be a cytoplasmically located protein whereas we and others have shown previously that LKB1 is predominantly nuclear, with only a small proportion of cells showing strong cytoplasmic expression. However, when LKB1 and LIP1 are co-expressed, the proportion of cytoplasmic LKB1 dramatically increases, suggesting that LIP1 may regulate LKB1 function by controlling its subcellular localization. Ectopic expression of both LKB1 and LIP1 in Xenopus embryos induces a secondary body axis, providing further evidence for a functional link between the two proteins. This phenotype resembles the effects of ectopic expression of TGFbeta superfamily members and their downstream effectors. A possible role for LIP1 and LKB1 in TGFbeta signalling is supported by the observation that LIP1 interacts with the TGFbeta-regulated transcription factor SMAD4, forming a LKB1-LIP1-SMAD4 ternary complex. SMAD4 mutations give rise to juvenile polyposis syndrome, which is clinically similar to PJS. Our data suggest an unsuspected mechanistic link between these two syndromes.
Subject(s)
Carrier Proteins , Nerve Growth Factors/metabolism , Peptide Fragments/metabolism , Peutz-Jeghers Syndrome/enzymology , Protein Serine-Threonine Kinases/metabolism , Proteins , Xenopus Proteins , AMP-Activated Protein Kinase Kinases , AMP-Activated Protein Kinases , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Animals , Cell Nucleus/enzymology , Chromosomes, Human, Pair 2/genetics , Cytoplasm/enzymology , DNA-Binding Proteins/metabolism , Gene Expression , HeLa Cells/cytology , Humans , Intracellular Signaling Peptides and Proteins , Mice , Molecular Sequence Data , Mutation , Nerve Growth Factors/genetics , Peptide Fragments/genetics , Peutz-Jeghers Syndrome/genetics , Precipitin Tests , Sequence Homology, Amino Acid , Signal Transduction , Smad Proteins , Smad4 Protein , Trans-Activators/metabolism , Xenopus laevis/embryology , Xenopus laevis/genetics , Xenopus laevis/metabolismABSTRACT
It has recently been shown that Ras proteins interact directly with Raf serine/threonine kinases in vitro and in the yeast two-hybrid system, leading to speculation that Raf proteins function as effectors for Ras. Here it is demonstrated that the endogenous Raf-1 protein co-immunoprecipitates with Ras from mammalian cells when the non-neutralizing anti-Ras monoclonal antibody Y13-238 is used. The formation of a Ras-Raf complex is absolutely dependent on prior treatment of the cells with a stimulus that activates Ras: phorbol ester or anti-T cell receptor antibody in the case of human peripheral blood T lymphoblasts, or epidermal growth factor in the case of Rat-1 fibroblasts. Up to 3% of cellular Raf-1 can be found in association with Ras. The association is not competed by addition of exogenous GST-Raf to the cell lysates and is therefore unlikely to be due to Ras-Raf binding after cell lysis. Specific interaction of Ras and Raf therefore occurs in intact mammalian cells in response to stimuli that cause Ras to become GTP-bound.
Subject(s)
Proto-Oncogene Proteins p21(ras)/metabolism , Proto-Oncogene Proteins/metabolism , Animals , Cells, Cultured , Epidermal Growth Factor/pharmacology , ErbB Receptors/physiology , Guanosine Triphosphate/metabolism , Humans , In Vitro Techniques , Lymphocyte Activation , Protein Binding , Proto-Oncogene Proteins c-raf , Rats , T-Lymphocytes/metabolismABSTRACT
It has been shown previously in T cells that stimulation of protein kinase C or the T cell antigen receptor leads to a rapid and persistent activation of p21ras as measured by a dramatic increase in the amount of bound GTP. These stimuli are also known to induce the expression of the T lymphocyte growth factor, interleukin-2 (IL-2), an essential growth factor for the immune system. Receptor induced activation of p21ras has been demonstrated in several cell types but involvement of protein kinase C as an upstream activator of p21ras appears to be unique to T cells. In this study we show that p21ras acts as a component of the protein kinase C and T cell antigen receptor downstream signalling pathway controlling IL-2 gene expression. In the murine T cell line EL4, constitutively active p21ras greatly potentiates the phorbol ester and T cell receptor agonist induced production of IL-2 as measured both by biological assay for the cytokine and by the use of a reporter construct. Active p21ras also partially replaces the requirement for protein kinase C activation in synergizing with a calcium ionophore to induce production of IL-2. Furthermore, using a dominant negative mutant of ras, Ha-rasN17, we show that endogenous ras function is essential for induction of IL-2 expression in response to protein kinase C or T cell receptor stimulation. Activation of ras proteins is thus a necessary but not sufficient event in the induction of IL-2 synthesis. Ras proteins are therefore pivotal signalling molecules in T cell activation.
Subject(s)
Interleukin-2/genetics , Lymphocyte Activation , Promoter Regions, Genetic , Proto-Oncogene Proteins p21(ras)/metabolism , T-Lymphocytes/immunology , Animals , Calcium/metabolism , Chloramphenicol O-Acetyltransferase/genetics , Enzyme Activation , Interleukin-2/biosynthesis , Lymphocyte Activation/genetics , Mice , Plasmids , Protein Kinase C/metabolism , Signal Transduction , Tumor Cells, CulturedSubject(s)
Abelson murine leukemia virus/genetics , Protein-Tyrosine Kinases/isolation & purification , Proto-Oncogene Proteins c-abl/isolation & purification , Abelson murine leukemia virus/enzymology , Animals , Chromatography/methods , Chromatography, Affinity/methods , Chromatography, DEAE-Cellulose/methods , Chromatography, Gel/methods , Chromatography, Ion Exchange/methods , Cloning, Molecular/methods , Durapatite , Escherichia coli/enzymology , Escherichia coli/genetics , Humans , Hydroxyapatites , Kinetics , Molecular Weight , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins c-abl/genetics , Proto-Oncogene Proteins c-abl/metabolism , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , TransfectionABSTRACT
The chromosome 22 derivative, the Philadelphia (Ph) chromosome, results from a reciprocal translocation t(9;22) (q34;q11) and is associated with chronic myeloid leukemia (CML). The translocation can be identified at the DNA level in Ph-positive CML by using a probe to the breakpoint cluster region (bcr). In addition, as a result of this translocation an abl-related 210-kd protein with protein tyrosine kinase (PTK) activity is produced. We analyzed 28 cases of Ph-negative CML for rearrangement of the chromosome 22 sequences and found that eight of the 28 show rearrangement of the bcr. When 12 of the Ph-negative cases were independently reviewed, five were indistinguishable from Ph-positive CML on the basis of morphology, peripheral blood film and clinical details. These five also showed bcr rearrangement. The other seven were reclassified as six atypical CML (aCML) and one chronic myelomonocytic leukemia (CMML). None of these seven showed bcr rearrangement. In addition 11 cases of bcr- CML were assayed for abl-related PTK, and no detectable activity was present, whereas p210 phl/abl PTK was observed both in Ph-positive (three cases examined) and Ph-negative, bcr + (four cases examined) CML. Therefore, bcr + CML, whether or not the Ph chromosome is cytogenetically apparent, involves a similar molecular alteration and produces the 210-kd protein with enhanced PTK activity. Furthermore, these cases can be distinguished from Ph-negative bcr- CML by careful evaluation of clinical and hematologic data.
Subject(s)
Chromosomes, Human, Pair 22 , Chromosomes, Human, Pair 9 , Leukemia, Myeloid/genetics , Myeloproliferative Disorders/genetics , Neoplasm Proteins/genetics , Philadelphia Chromosome , DNA, Neoplasm/genetics , Humans , Leukemia, Myeloid/pathology , Neoplasm Proteins/metabolism , Protein-Tyrosine Kinases/genetics , Proto-Oncogene Proteins/genetics , Proto-OncogenesABSTRACT
An aberrant p210BCR-ABL protein that possesses constitutive protein-tyrosine kinase activity is presumed to be involved in the development of the neoplastic phenotype in chronic myelogenous leukemia (CML). Using a highly specific antibody against phosphotyrosine, we have isolated the tyrosine-phosphorylated p210BCR-ABL and several other proteins containing phosphotyrosine from a variety of CML cell lines. p210BCR-ABL isolated by the monoclonal anti-phosphotyrosine antibody possessed protein-tyrosine kinase activity in vitro comparable to that of the p210BCR-ABL isolated by antibody to a specific peptide sequence in the ABL protein-tyrosine kinase. Other prominent proteins containing phosphorylated tyrosine residues were observed at 185, 150, 120, 105, 63, 56, 36, and 32 kDa, and less prominent proteins were observed at 195, 155, 94, 53, 40, and less than 29 kDa. Staphylococcal V8 peptide mapping indicated that proteins of similar molecular weights were highly homologous to each other across cell lines, despite the diverse hematopoietic lineages of these cells and the genetic heterogeneity of the patients from whom the CML cell lines were derived. Phosphopeptide mapping also revealed that these proteins were distinct from each other as well as from p210BCR-ABL. Because virtually identical phosphotyrosine-containing proteins were found in peripheral blood leukocytes taken directly from CML patients, these proteins are not an artifact of long-term tissue culture but appear to be an integral part of the CML phenotype.
Subject(s)
Leukemia, Myeloid/metabolism , Neoplasm Proteins/analysis , Phosphoproteins/analysis , Recombinant Fusion Proteins/metabolism , Recombinant Proteins/metabolism , Tyrosine/analogs & derivatives , Amino Acid Sequence , Blast Crisis/blood , Blood Proteins/analysis , Cell Line , Fusion Proteins, bcr-abl , Humans , Leukocytes/analysis , Peptide Mapping , Phosphorylation , Phosphotyrosine , Tyrosine/analysisABSTRACT
The Philadelphia (Ph) chromosome breakpoints in chronic myelocytic leukaemia are clustered on chromosome 22 band q11 in a 5.8-kilobase (kb) region designated bcr. The c-abl protooncogene is translocated from chromosome 9 band q34 into bcr and the biochemical consequence of this molecular rearrangement is the production of an abnormal fusion protein bcr-abl p210 with enhanced protein-tyrosine kinase activity compared to the normal p145 c-abl protein. The Ph chromosome translocation is also seen in some acute lymphoblastic leukaemias with B-cell precursor phenotypes some of which have bcr rearrangement (bcr+) and some do not (bcr-). We present evidence that the Ph+, bcr- leukaemias are associated with a novel p190 abl kinase. We propose that acute lymphoblastic leukaemias that are bcr+, p210+ are probably lymphoid blast crises following a clinically silent chronic phase of chronic myelocytic leukaemia arising in multipotential stem cells whereas bcr-, p190+ cases are de novo acute lymphoblastic leukaemias arising in more restricted precursors.